{"podcast":{"title":"Breast Cancer Update","slug":"breast-cancer-update-757579","podcast_index_feed_id":757579,"rss_url":"https://feeds.captivate.fm/breast-oncology/","website_url":"https://www.researchtopractice.com/browse-by-tumor-types/breast-cancer","image_url":"https://artwork.captivate.fm/ad97e2be-455a-4b53-ab3d-383838c145e5/cbjJP3tyd5NWFP4W5DD1CnhC.png","author":"Dr. Neil Love","episode_count":118,"summary":"Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.","last_synced_at":"2026-09-22T02:17:02.774213+00:00","page_url":"https://stenobird.com/podcast/breast-cancer-update-757579"},"episode":{"title":"For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress","slug":"for-oncology-nurses-oral-selective-estrogen-receptor-degraders-in-breast-cancer-proceedings-from-the-2026-annual-ons-congress","published_at":"2026-08-18T16:00:00+00:00","page_url":"https://stenobird.com/podcast/breast-cancer-update-757579/for-oncology-nurses-oral-selective-estrogen-receptor-degraders-in-breast-cancer-proceedings-from-the-2026-annual-ons-congress","show_page_url":"https://stenobird.com/podcast/breast-cancer-update-757579","url":"https://breast-oncology.captivate.fm/episode/6100-ons2026-oralserdsbreast","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/db3da0a1-a5a2-4029-a22a-05213b6f0265.mp3","summary":"Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics: Introduction (0:00) Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37) Practical Considerations with Oral SERDs (15:42) Potential Role of Combination Approaches with Oral SERDs (26:31) Gastrointestinal Adverse Events Documented with Oral SERDs (38:17) Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:51) Other Class-Effect Toxicities Associated with Oral SERDs (1:00:53) Emerging Utility of Adjuvant Oral SERDs (1:10:16) Unique Toxicities Associated with 1 or More Oral SERDs (1:19:17) CME information and select publications","meta_description":"Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the…","key_points":[],"chapters":[],"topics":[],"duration_seconds":5087,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/breast-cancer-update-757579/episodes/for-oncology-nurses-oral-selective-estrogen-receptor-degraders-in-breast-cancer-proceedings-from-the-2026-annual-ons-congress/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/breast-cancer-update-757579/for-oncology-nurses-oral-selective-estrogen-receptor-degraders-in-breast-cancer-proceedings-from-the-2026-annual-ons-congress.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}